MSCI reported earnings on July 21 and the market's verdict was swift: the stock dropped 10% in a single session, erasing all of the optimism that had built through a week of analyst target raises ahead of the print.
The earnings reaction is the story this week. Just days ago, the pre-earnings setup looked constructive — options were tilted bullish, analysts were raising hands, and the stock had climbed roughly 4% into the report. The gap from that $628 pre-earnings level to Tuesday's close of $561.74 is a meaningful reset. The next scheduled earnings event is October 20, giving the market three months to reassess.
The Street moved quickly to absorb the result. JP Morgan's analyst trimmed his target to $700 from $742 on the day of the print, while Evercore ISI cut to $722 from $746 — both maintaining positive ratings. Wells Fargo also lowered its target modestly, to $690 from $700, holding Overweight. The direction of travel is clear: constructive on the long-term story, less aggressive on near-term valuation. The consensus mean target now sits at $694, implying roughly 24% upside from current levels — the gap has widened sharply precisely because the stock fell, not because the Street turned negative. Jefferies' fresh Buy initiation at $760 from just last week still stands. No firm downgraded. The analyst community is trimming numbers but not waving the white flag.
Options positioning has swung sharply after the move. The put/call ratio jumped to 1.30 on the day of the drop before settling back to 1.12 on July 21 — essentially flat with its 20-day average of 1.11. That's a dramatic reversal from the pre-earnings PCR of 0.83, which was the most bullish options reading in months. The options market has repriced but has not yet tipped into outright defensive territory. The 52-week PCR high of 2.70 — hit during the defensive posture of late June — shows there is room to run higher if sentiment sours further. Borrow conditions add almost nothing to the picture here: short interest is just 1.7% of free float, availability is effectively unlimited, and cost to borrow at 0.43% is near its lowest level of the past 30 days. There is no short pressure and no squeeze dynamic to monitor.
The ownership backdrop offers one data point worth noting. CEO Henry Fernandez bought just over 4,000 shares across multiple tranches on May 15 at prices around $561–$565 — almost exactly where the stock closed this week after the selloff. That purchase, totalling roughly $2.25 million, now looks like it was timed near a support level the market has revisited. The CFO made a routine $272,000 sale in June, which is the only insider activity running the other direction. T. Rowe Price added 604,800 shares in the most recent reporting period, a notable addition from an active manager that suggests at least one institution was building into the weakness earlier in the year.
The valuation context cuts both ways. The PE multiple has compressed to roughly 26x on the selloff, down about 1.5 turns over the past 30 days, while EV/EBITDA has pulled back to around 20x. Those are still premium multiples for a business the bear case describes as facing decelerating ABF growth and declining net new subscriptions. The bull case — reaccelerating subscription revenue, 19% AUM growth, dominant market position across four segments — has not changed, but the market has clearly decided to pay less for it in the near term. Peers moved lower on the day too, with SPGI off 3.8% and MORN down 3.5%, though both are down far less on the week than MSCI's 8% decline, suggesting the earnings-specific response rather than a broad sector rotation drove the gap.
What to watch next is whether the $560–$562 level — where Fernandez bought in May and where the stock is now trading — acts as a base or gives way, and whether the three-month window to October earnings sees further analyst target cuts as the subscription-growth trajectory becomes clearer.
See the live data behind this article on ORTEX.
Open MSCI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
